<DOC>
	<DOCNO>NCT00640146</DOCNO>
	<brief_summary>The purpose study examine safety activity MNTX relieve opioid-induced constipation follow orthopedic procedure .</brief_summary>
	<brief_title>Study Subcutaneous Methylnaltrexone ( MNTX ) Treatment Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures</brief_title>
	<detailed_description>This double-blind , randomize , parallel-group , placebo- control phase 2 study evaluate safety activity subcutaneous ( SC ) MNTX versus SC placebo subject undergone orthopedic procedure expect require opioids one week randomization . Subjects sign informed consent form screen Days 4-10 orthopedic procedure . Those subject meet eligibility requirement enrol study . Subjects randomly assign either four-day treatment daily SC MNTX 12 mg SC placebo 1:1 ratio . Treatment study medication begin day screening , later follow calendar day . All bowel movement time bowel movement record . Treatment study medication continue either subject long require opioid medication pain relief maximum four day ( four dos ) treatment reach . Subjects give patient diary start study . Study drug transfer hospital rehabilitation facility subject discharge rehabilitation facility .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>1 . Male female subject Â³ 18 year age . 2 . Subjects must undergo orthopedic procedure ( i.e. , total knee hip replacement , spinal fusion reduction fracture ( ) without surgical fixation post trauma ) . 3 . Subjects must receive opioid medication pain relief procedure 4 . Subjects must constipate follow orthopedic procedure 5 . Subjects must receive dos study drug either hospital rehabilitation facility . 6 . Subjects must sign informed consent form . 7 . Females childbearing potential must negative pregnancy test use appropriate birth control throughout study . 8 . Body weight within range 40 kg 150 kg ( 88 330 lb ) . 1 . Subjects know hypersensitivity methylnaltrexone , naltrexone , naloxone . 2 . Subjects receive investigational new drug ( experimental ) previous 30 day . 3 . Subjects receive osmotic laxative ( e.g. , lactulose ) enema within 48 hour prior first dose . 4 . Subjects initiated treatment stool softener within 24 hour prior first dose . 5 . Subjects constipation attribute post procedure opioids 6 . Subjects history alcohol prescription nonprescription drug abuse within past two year . 7 . Female subject pregnant lactating . 8 . Subjects know history chronic active hepatitis B hepatitis C virus human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>